Johnson & Johnson Innovation names finalists in atopic advancements QuickPitch

Johnson & Johnson Innovation, together with Johnson & Johnson Innovative Medicine, is proud to announce that Artelo Biosciences, Enveda Biosciences and Noa Therapeutics have been named as finalists in the Atopic Advancements QuickPitch. The live pitch was held on March 11 at JLABS San Diego during the 2024 American Academy of Dermatology (AAD) Annual Meeting.

Johnson & Johnson Innovation is committed harnessing the power of breakthrough therapeutics to create a brighter future for the estimated 223 million individuals worldwide living with atopic dermatitis. The challenge invited innovators from across the globe to submit their novel orally administered therapeutics that have indications in atopic dermatitis with the aim of improving quality of life for these patients.

Artelo Biosciences – Artelo was founded in 2017 on the promise of therapeutic development based on lipid-signaling modification, including inhibiting Fatty Acid Binding Protein 5 (FABP5 or Epidermal FABP) which is a novel molecular target for the treatment of dermatology conditions.

Enveda Biosciences – Enveda Biosciences aims to transform small molecule drug discovery with machine learning & metabolomics.

Noa Therapeutics - Noa Therapeutics is a preclinical biotech company seeking to pioneer the development of non-steroidal, tri-modal small molecules to address the complexity of inflammatory barrier diseases, such as atopic dermatitis and ulcerative colitis/IBD, by simultaneously targeting three key disease drivers to reduce the cycle of treatment failures.

The finalists were selected due to their potentially breakthrough science and presented their ideas in a closed-door pitch session with a panel of Johnson & Johnson Innovative Medicine leaders on March 11th.